Phage therapy treats infections with viruses that attack bacteria, and matching a phage to a strain still depends on time-consuming lab work, according to Camino Science's EIC project. Camino Science, registered in Białystok in eastern Poland in 2020, builds AI models meant to "predict given phage effectiveness against a specific bacteria strain", point to mutations that make a phage more effective and explain the predictions, as the project objective puts it.
The European Innovation Council granted €1,692,596 towards a €2.4 million project from January 2023 to May 2025, with the target of cutting "90 out of 100 experiments". The final report says model accuracy improved "between 2% - 5% compared to previous versions" and that the work produced material for international patent applications. It lists "additional laboratory studies validating AI predictions" as a need still to be met. The company's filed accounts, published by BizRaport, show a net loss of PLN 682,530 in 2025 and negative equity of PLN 1.69 million.
Company file
- Legal entity
- Camino Science sp. z o.o., KRS 0000835843, Białystok
- Registered
- 25 March 2020
- Share capital
- PLN 63,000
- Employees
- 2 to 10, estimated
- Product
- InSilico Camino, AI prediction of phage-host interactions
- EIC project
- in silico bio-evolutio, 1 Jan 2023 to 31 May 2025
- EIC funding
- Grant first
Where Camino Science Stands Now
Camino Science has announced no customer, partner, funding round or product launch that we could find. Its website's security certificate had expired when checked in September 2026. According to North Data, it filed a patent application in May 2024 for a "Computer-Aided Method for Modeling Phage-Host Interactions". The company reported revenue of PLN 2.22 million in 2025; the accounts summary does not say how much of it came from grants.
The Technology: Simulating the Lab
Before the EIC award, Camino Science had already received PLN 844,434 from the EU's Eastern Poland programme for InSilico Camino, a 2021 to 2023 project to build an AI platform simulating virus experiments, according to Poland's EU grants map. That project claimed the platform could cut experiments by 95% to 99%. The EIC project extended the idea to personalised phage therapy and to probiotics for the microbiome.
What the EIC Project Promised, and What CORDIS Shows
The EIC was told the platform would remove 90 out of every 100 experiments. What the final report shows is a 2% to 5% gain in model accuracy over the company's earlier versions, "complex insights behind the given predictions" and patent material. The report's own list of next steps begins with lab studies to validate the AI's predictions, the test of whether the core promise holds. CORDIS still lists the project as signed.
- Improved prediction modelsDelivered2% to 5% more accurate.
- Patent protectionFiledApplication, May 2024.
- 90% fewer lab experimentsNot shownLab validation pending.
- CustomersNone namedNo announcement found.
The Money
Camino Science made small profits in 2021 and 2022, then lost PLN 1.14 million in 2023, PLN 53,189 in 2024 and PLN 682,530 in 2025. Its equity has been negative at the end of each of the last three years, reaching minus PLN 1.69 million in 2025, with total assets of PLN 2.25 million. Revenue moved between PLN 740,000 and PLN 2.2 million.
What Cannot Be Checked
Questions for the EIC
Whether any lab has confirmed the platform's predictions, how much of Camino Science's revenue is from customers rather than grants, and how it will fund the validation studies its report calls for are not public.
Why Europe Should Care
The EIC backed a very small Polish company working on phage therapy, after a regional EU grant had already funded the same idea. After both grants, the claim that AI can replace most phage lab work is still waiting for its first published lab test.
What the project promised
AI simulation replacing 90 out of 100 lab experiments in phage therapy development.
What the record shows
A 2% to 5% model improvement, a patent application, no lab validation, and negative equity.
The Verdict
A big promise, a small step
Camino Science improved its models and filed a patent. The promise that won it EIC money, replacing nine in ten experiments, has not been tested in a lab, and the company's balance sheet is under water.
Camino Science and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.
